Prevalence of microcephaly and Zika virus infection in a pregnancy cohort in Kenya, 2017-2019.
Kenya
Microcephaly
Pregnancy
Zika virus
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
14 09 2022
14 09 2022
Historique:
received:
10
02
2022
accepted:
25
07
2022
entrez:
13
9
2022
pubmed:
14
9
2022
medline:
16
9
2022
Statut:
epublish
Résumé
Zika virus (ZIKV), first discovered in Uganda in 1947, re-emerged globally in 2013 and was later associated with microcephaly and other birth defects. We determined the incidence of ZIKV infection and its association with adverse pregnancy and fetal outcomes in a pregnancy cohort in Kenya. From October 2017 to July 2019, we recruited and followed up women aged ≥ 15 years and ≤ 28 weeks pregnant in three hospitals in coastal Mombasa. Monthly follow-up included risk factor questions and a blood sample collected for ZIKV serology. We collected anthropometric measures (including head circumference), cord blood, venous blood from newborns, and any evidence of birth defects. Microcephaly was defined as a head circumference (HC) < 2 standard deviations (SD) for sex and gestational age. Severe microcephaly was defined as HC < 3 SD for sex and age. We tested sera for anti-ZIKV IgM antibodies using capture enzyme-linked immunosorbent assay (ELISA) and confirmed positives using the plaque reduction neutralization test (PRNT Of 2889 pregnant women screened for eligibility, 2312 (80%) were enrolled. Of 1916 recorded deliveries, 1816 (94.6%) were live births and 100 (5.2%) were either stillbirths or spontaneous abortions (< 22 weeks of gestation). Among 1236 newborns with complete anthropometric measures, 11 (0.9%) had microcephaly and 3 (0.2%) had severe microcephaly. A total of 166 (7.2%) participants were positive for anti-ZIKV IgM, 136 of whom became seropositive during follow-up. Among the 166 anti-ZIKV IgM positive, 3 and 18 participants were further seropositive for ZIKV and DENV neutralizing antibodies, respectively. Of these 3 and 18 pregnant women, one and 13 (72.2%) seroconverted with antibodies to ZIKV and DENV, respectively. All 308 samples (serum and urine samples collected during sick visits and samples that were anti-ZIKV IgM positive) tested by RT-PCR were negative for ZIKV. No adverse pregnancy or neonatal outcomes were reported among the three participants with confirmed ZIKV exposure. Among newborns from pregnant women with DENV exposure, four (22.2%) were small for gestational age and one (5.6%) had microcephaly. The prevalence of severe microcephaly among newborns in coastal Kenya was high relative to published estimates from facility-based studies in Europe and Latin America, but little evidence of ZIKV transmission. There is a need for improved surveillance for microcephaly and other congenital malformations in Kenya.
Sections du résumé
BACKGROUND
Zika virus (ZIKV), first discovered in Uganda in 1947, re-emerged globally in 2013 and was later associated with microcephaly and other birth defects. We determined the incidence of ZIKV infection and its association with adverse pregnancy and fetal outcomes in a pregnancy cohort in Kenya.
METHODS
From October 2017 to July 2019, we recruited and followed up women aged ≥ 15 years and ≤ 28 weeks pregnant in three hospitals in coastal Mombasa. Monthly follow-up included risk factor questions and a blood sample collected for ZIKV serology. We collected anthropometric measures (including head circumference), cord blood, venous blood from newborns, and any evidence of birth defects. Microcephaly was defined as a head circumference (HC) < 2 standard deviations (SD) for sex and gestational age. Severe microcephaly was defined as HC < 3 SD for sex and age. We tested sera for anti-ZIKV IgM antibodies using capture enzyme-linked immunosorbent assay (ELISA) and confirmed positives using the plaque reduction neutralization test (PRNT
RESULTS
Of 2889 pregnant women screened for eligibility, 2312 (80%) were enrolled. Of 1916 recorded deliveries, 1816 (94.6%) were live births and 100 (5.2%) were either stillbirths or spontaneous abortions (< 22 weeks of gestation). Among 1236 newborns with complete anthropometric measures, 11 (0.9%) had microcephaly and 3 (0.2%) had severe microcephaly. A total of 166 (7.2%) participants were positive for anti-ZIKV IgM, 136 of whom became seropositive during follow-up. Among the 166 anti-ZIKV IgM positive, 3 and 18 participants were further seropositive for ZIKV and DENV neutralizing antibodies, respectively. Of these 3 and 18 pregnant women, one and 13 (72.2%) seroconverted with antibodies to ZIKV and DENV, respectively. All 308 samples (serum and urine samples collected during sick visits and samples that were anti-ZIKV IgM positive) tested by RT-PCR were negative for ZIKV. No adverse pregnancy or neonatal outcomes were reported among the three participants with confirmed ZIKV exposure. Among newborns from pregnant women with DENV exposure, four (22.2%) were small for gestational age and one (5.6%) had microcephaly.
CONCLUSIONS
The prevalence of severe microcephaly among newborns in coastal Kenya was high relative to published estimates from facility-based studies in Europe and Latin America, but little evidence of ZIKV transmission. There is a need for improved surveillance for microcephaly and other congenital malformations in Kenya.
Identifiants
pubmed: 36100910
doi: 10.1186/s12916-022-02498-8
pii: 10.1186/s12916-022-02498-8
pmc: PMC9470235
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin M
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
291Subventions
Organisme : ACL HHS
ID : U01GH002143
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Gen Virol. 2018 Sep;99(9):1248-1252
pubmed: 29975185
BMJ. 2016 Sep 13;354:i4721
pubmed: 27623840
Front Immunol. 2020 Feb 26;11:334
pubmed: 32174923
Sci Rep. 2020 Jul 29;10(1):12673
pubmed: 32728054
Nat Commun. 2019 Dec 16;10(1):5730
pubmed: 31844054
J Infect Dis. 2020 Aug 4;222(5):847-852
pubmed: 32242626
Emerg Infect Dis. 2019 Aug;25(8):1452-1460
pubmed: 31310215
BMC Infect Dis. 2020 May 11;20(1):332
pubmed: 32393198
Nat Commun. 2021 Feb 10;12(1):916
pubmed: 33568638
Science. 2020 Nov 20;370(6519):991-996
pubmed: 33214283
Bull World Health Organ. 2016 Jun 1;94(6):406-406A
pubmed: 27274588
BMC Pregnancy Childbirth. 2021 Mar 17;21(1):214
pubmed: 33731027
Emerg Infect Dis. 2018 Sep;24(9):1748-1750
pubmed: 30124410
Virol J. 2019 May 17;16(1):65
pubmed: 31101058
BMJ. 2017 Nov 21;359:j5018
pubmed: 29162597
Ultrasound Obstet Gynecol. 2017 Jun;49(6):729-736
pubmed: 28078779
Lancet Infect Dis. 2019 Oct;19(10):1138-1147
pubmed: 31559967
Proc Biol Sci. 2019 Aug 28;286(1909):20191578
pubmed: 31455188
Virol J. 2016 Nov 4;13(1):182
pubmed: 27814732
Virus Evol. 2020 Jun 02;6(1):veaa026
pubmed: 32523778
Viruses. 2020 Jun 13;12(6):
pubmed: 32545775
Wellcome Open Res. 2019 Nov 15;4:179
pubmed: 32175480
Emerg Infect Dis. 2017 Feb;23(2):296-299
pubmed: 27875110
PLoS One. 2020 Dec 15;15(12):e0242367
pubmed: 33320867
Viral Immunol. 2008 Jun;21(2):123-32
pubmed: 18476771
Int J Environ Res Public Health. 2018 Jan 28;15(2):
pubmed: 29382107
Mem Inst Oswaldo Cruz. 2016 Sep;111(9):559-60
pubmed: 27653360
N Engl J Med. 2016 Dec 15;375(24):2321-2334
pubmed: 26943629
Matern Health Neonatol Perinatol. 2017 Oct 3;3:17
pubmed: 29026637
Am J Trop Med Hyg. 2018 Sep;99(3):756-763
pubmed: 29988000
Lancet. 2014 Sep 6;384(9946):857-68
pubmed: 25209487
PLoS One. 2016 Apr 11;11(4):e0151586
pubmed: 27064786
Emerg Infect Dis. 2020 Jul;26(7):1603-1605
pubmed: 32568041
J Infect Dev Ctries. 2010 Nov 24;4(11):767-75
pubmed: 21252457
PLoS Curr. 2018 Mar 15;10:
pubmed: 29637009
F1000Res. 2018 Feb 15;7:196
pubmed: 30631437